PALVELLA THERAPEUTICS, INC.
PVLA · XNASCIK 1583648fmd_1Y8RMYYKZ8G0ES2MM45RZ7D6DPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 53 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 25 | 29 | 46 | 29 | 31 | 26 | 43 | – | – |
| Net interest income | – | – | – | – | – | – | – | – | 1 | 3 |
| Realized investment gains (losses) | – | 0 | 1 | 0 | – | 0 | 0 | 0 | – | – |
| Research and development | 20 | 22 | 41 | 55 | 47 | 67 | 53 | 9 | 8 | 23 |
| Total operating expenses | 29 | 40 | 60 | 73 | 63 | 83 | 69 | 12 | 14 | 39 |
| Operating income | (23) | (15) | (31) | (27) | (34) | (52) | (43) | (12) | (14) | (39) |
| Interest expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | (2) | 2 | (0) | (4) | 2 | 1 | 1 | (0) | 1 |
| Income before taxes | (23) | (17) | (27) | (25) | (37) | (46) | (33) | 19 | (17) | (42) |
| Income tax expense | 0 | 1 | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (23) | (18) | (27) | (25) | (37) | (46) | (33) | 19 | (17) | (42) |
| Net income | (23) | (18) | (27) | (25) | (37) | (46) | (33) | 19 | (17) | (42) |
| Net income to common shareholders | – | – | (27) | (28) | (37) | – | – | 18 | (17) | – |